

Is Cabergoline still in shortage in 2026? Get the latest update on availability, pricing, and what patients can do to find their medication.
If you take Cabergoline, you've probably experienced the frustration of going to your pharmacy and being told it's not in stock. You're not imagining things — Cabergoline has had ongoing supply challenges that have made it harder for patients to fill their prescriptions reliably.
Here's what you need to know about the current state of Cabergoline availability, why it's been difficult to find, and what you can do about it.
As of early 2026, Cabergoline is not formally listed on the FDA Drug Shortage Database. That's the official list maintained by the FDA tracking medications with confirmed supply disruptions.
However, "not on the shortage list" doesn't mean it's easy to find. Many patients and pharmacies continue to report intermittent supply disruptions. The disconnect happens because:
In practical terms, if you're having trouble finding Cabergoline at your pharmacy, you're experiencing a real supply problem even if it's not officially classified as a "shortage."
Several factors have contributed to Cabergoline's availability challenges:
Only a handful of companies produce generic Cabergoline tablets in the U.S. Teva Pharmaceuticals is the primary manufacturer. When any one producer has a supply disruption — whether from raw material issues, production delays, or quality inspections — the impact is felt widely.
Cabergoline treats hyperprolactinemia and prolactinomas — conditions that affect a relatively small number of patients compared to chronic diseases like diabetes or hypertension. This means pharmacies don't stock it in large quantities, and wholesaler inventories may be limited.
As an ergot-derived medication, Cabergoline requires specialized manufacturing processes that not every generic pharmaceutical company is equipped to handle. This limits the number of potential producers who could enter the market to ease supply pressure.
Cabergoline has seen increased interest for off-label uses, including in various endocrine conditions. Any increase in prescribing puts additional pressure on an already limited supply.
Cost adds another layer of complexity. Here's what you can expect to pay:
Since Cabergoline is taken just twice a week, a bottle of 8 tablets can last about a month at the standard maintenance dose. That keeps monthly costs manageable for most patients, especially with a discount coupon.
For more detailed savings strategies, see our full guide: How to Save Money on Cabergoline in 2026.
While no new dopamine agonists have been approved specifically for hyperprolactinemia recently, patients in 2026 have more tools than ever to navigate supply challenges:
If you need to fill a Cabergoline prescription today, here's your action plan:
For a deeper dive into finding strategies, read: How to Find Cabergoline in Stock Near You.
The Cabergoline supply situation in 2026 is imperfect but manageable. The medication is being produced, and most patients who are proactive about searching can find it. The challenge is that it requires more effort than picking up a common generic at any corner pharmacy.
Stay informed, plan ahead with your refills, and use tools like Medfinder to make the process easier. And if you're struggling, don't hesitate to reach out to your endocrinologist — they deal with this issue regularly and can help you stay on track with your treatment.
For the provider perspective on this issue, see Cabergoline Shortage: What Providers and Prescribers Need to Know in 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.